Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.46 |
| ▸ | WNT3A | P56704 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PPID | Q08752 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421799 | 0.85 | P2RX7 (0.54) | P2RX7FAAHCTNNB1WNT3AMEN1 | |
| SCHEMBL29508230 | 0.80 | CYP1A2 (0.53) | P2RX7FAAHCTNNB1WNT3ANAMPT | |
| SCHEMBL917137 | 0.80 | CYP1A2 (0.53) | P2RX7FAAHCTNNB1WNT3ANAMPT | |
| SCHEMBL5160865 | 0.80 | P2RX7 (0.49) | P2RX7FAAHCTNNB1WNT3AKDM4E | |
| SCHEMBL5161597 | 0.80 | P2RX7 (0.49) | P2RX7FAAHCTNNB1WNT3AKMT2A | |
| SCHEMBL601821 | 0.79 | LMNA (0.54) | CTNNB1WNT3AGAAPKMKDM4E | |
| Hydrochloric Acid SCHEMBL27922723 | 0.79 | CYP1A2 (0.51) | P2RX7FAAHCTNNB1WNT3ANAMPT | |
| SCHEMBL12999382 | 0.79 | P2RX7 (0.51) | P2RX7FAAHNAMPTKDM4EMEN1 | |
| SCHEMBL12208551 | 0.78 | P2RX7 (0.58) | P2RX7FAAHCTNNB1WNT3APKM | |
| SCHEMBL5160376 | 0.78 | CYP3A4 (0.49) | P2RX7FAAHCTNNB1WNT3AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415795-B2 | 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | NXERA PHARMA UK LIMITED (GB) | 2025-09-16 | — | — | US | disclosed |
| US-20240092754-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | NXERA PHARMA UK LIMITED (GB) | 2024-03-21 | — | — | US | disclosed |
| US-11680053-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-06-20 | — | — | US | disclosed |
| US-11680053-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-06-20 | — | — | US | disclosed |
| US-11680053-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-06-20 | — | — | US | disclosed |
| US-11584732-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-11584732-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20220056009-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | NXERA PHARMA UK LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-20220056009-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | NXERA PHARMA UK LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-20210309632-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | NXERA PHARMA UK LIMITED (GB) | 2021-10-07 | — | — | US | disclosed |
| WO-2003072580-A1 | 1-[ALKYL], 1-[HETEROARYL)ALKYL] AND 1-[ARYL)ALKYL]-7-(PYRIMIDIN-4-YL)-IMADAZO[1,2-a]PYRIMIDIN-5(1H)-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003072579-A1 | HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9- TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2003-09-04 | — | — | WO | disclosed |
| EP-1340760-A1 | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives | SANOFI-SYNTHELABO (FR) | 2003-09-03 | — | — | EP | disclosed |
| EP-1340759-A1 | 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives | SANOFI-SYNTHELABO (FR) | 2003-09-03 | — | — | EP | disclosed |
| EP-1340746-A1 | Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives | BAYER AG (DE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003027080-A1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027115-A1 | SUBSTITUTED 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIMIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES FOR NEURODEGENERATIVE DISORDERS | SANOFI-SYNTHELABO (FR) | 2003-04-03 | — | — | WO | disclosed |
| EP-1295884-A1 | 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives | SANOFI-SYNTHELABO (FR) | 2003-03-26 | — | — | EP | disclosed |
| US-4145423-A | TREATMENT OF SCHISTOSOMIASIS AND AMOEBIASIS, NEMATODES, ANTIPROTAZOA | RHONE-POULENC INDUSTRIES (FR) | 1979-03-20 | — | — | US | disclosed |
| US-4104386-A | Derivatives of 1,2-dithiole and anti-bilharzia compositions thereof | RHONE-POULENC INDUSTRIES (FR) | 1978-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680053-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | GRM5, GRM2, GRM6 | P2RX7 77/4885FAAH 187/4885CTNNB1 4212/4885 |
| US-11584732-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | GRM5, GRM2, GRM6 | P2RX7 77/4885FAAH 187/4885CTNNB1 4212/4885 |
| US-12415795-B2 | 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | GRM5, GRM6, GRM2 | P2RX7 75/4885FAAH 215/4885CTNNB1 4051/4885 |
| US-20240092754-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | GRM5, GRM6, GRM2 | P2RX7 75/4885FAAH 215/4885CTNNB1 4051/4885 |
| US-20220056009-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | GRM5, GRM6, GRM2 | P2RX7 75/4885FAAH 215/4885CTNNB1 4051/4885 |
| US-20210309632-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | GRM5, GRM6, GRM2 | P2RX7 75/4885FAAH 215/4885CTNNB1 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.